ArticleNature immunology2015
Protein kinase CK2 enables regulatory T cells to suppress excessive TH2 responses in vivo.
Article in Nature immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- CSNK2 in cancer: pathophysiology and translational applications.British journal of cancer · 2022Pooled it
- In or out of control: Modulating regulatory T cell homeostasis and function with immune checkpoint pathways.Frontiers in immunology · 2022Pooled it
- Type 2 conventional dendritic cells and regulatory T cells form a barrier tissue circuit to control allergic inflammation.bioRxiv : the preprint server for biology · 2026Article
- CK2 in the spotlight: decoding its role in hematological malignancies and therapeutic applications.Discover oncology · 2025Review
- Tissue-Resident Th2 Cells in Type 2 Immunity and Allergic Diseases.Immunological reviews · 2025Review
- The immunobiology and therapeutic potential of regulatory T cells in autoimmune diseases and allergic diseases.Frontiers in immunology · 2025Review
- Scoping Pleiotropy of CK2 in Musculoskeletal Disorders for a Novel Targeting Approach.Kinases and phosphatases · 2024Article
- Cell cycle-dependent gene networks for cell proliferation activated by nuclear CK2α complexes.Life science alliance · 2024Article
- Randomized, Double-Blind, Placebo-Controlled Trial of Vitamin D Supplementation in the Build-up Phase of House Dust Mite-Specific Immunotherapy.Allergy, asthma & immunology research · 2023Article
- Antibody therapies for the treatment of acute myeloid leukemia: exploring current and emerging therapeutic targets.Expert opinion on investigational drugs · 2023Review
- Protein Kinase CK2 Controls CD8Journal of immunology (Baltimore, Md. : 1950) · 2022Article
- CK2 and the Hallmarks of Cancer.Biomedicines · 2022Review
- Regulation of sclerostin by the SIRT1 stabilization pathway in osteocytes.Cell death and differentiation · 2022Article
- Diversity of T Helper and Regulatory T Cells and Their Contribution to the Pathogenesis of Allergic Diseases.Handbook of experimental pharmacology · 2022Article
- Regulatory T Cells, a Viable Target Against Airway Allergic Inflammatory Responses in Asthma.Frontiers in immunology · 2022Review
- Current Strategies to Modulate Regulatory T Cell Activity in Allergic Inflammation.Frontiers in immunology · 2022Review
- Immunogenetics of Lupus Erythematosus.Advances in experimental medicine and biology · 2022Article
- The Immune Regulatory Role of Protein Kinase CK2 and Its Implications for Treatment of Cancer.Biomedicines · 2021Review
- Protein Kinase CK2 Regulates B Cell Development and Differentiation.Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy.The Journal of experimental medicine · 2021Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
30 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The quality of the adaptive immune response depends on the differentiation of distinct CD4(+) helper T cell subsets, and the magnitude of an immune response is controlled by CD4(+)Foxp3(+) regulatory T cells (Treg cells). However, how a tissue- and cell type-specific suppressor program of Treg cells is mechanistically orchestrated has remained largely unexplored. Through the use of Treg cell-specific gene targeting, we found that the suppression of allergic immune responses in the lungs mediated by T helper type 2 (TH2) cells was dependent on the activity of the protein kinase CK2. Genetic ablation of the β-subunit of CK2 specifically in Treg cells resulted in the proliferation of a hitherto-unexplored ILT3(+) Treg cell subpopulation that was unable to control the maturation of IRF4(+)PD-L2(+) dendritic cells required for the development of TH2 responses in vivo.
Indexed as
Identifiers
25599562What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.